CA2992509C - Anti-TFR antibodies and their use in the treatment of proliferative and inflammatory diseases - Google Patents

Anti-TFR antibodies and their use in the treatment of proliferative and inflammatory diseases

Info

Publication number
CA2992509C
CA2992509C CA2992509A CA2992509A CA2992509C CA 2992509 C CA2992509 C CA 2992509C CA 2992509 A CA2992509 A CA 2992509A CA 2992509 A CA2992509 A CA 2992509A CA 2992509 C CA2992509 C CA 2992509C
Authority
CA
Canada
Prior art keywords
antibody
seq
tfr
protein
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2992509A
Other languages
English (en)
French (fr)
Other versions
CA2992509A1 (en
Inventor
Pierre Launay
Coralie BELANGER
Herve Souchet
Original Assignee
Inatherys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inatherys filed Critical Inatherys
Publication of CA2992509A1 publication Critical patent/CA2992509A1/en
Application granted granted Critical
Publication of CA2992509C publication Critical patent/CA2992509C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA2992509A 2015-07-22 2016-07-21 Anti-TFR antibodies and their use in the treatment of proliferative and inflammatory diseases Active CA2992509C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306192 2015-07-22
EP15306192.4 2015-07-22
PCT/EP2016/067465 WO2017013230A1 (en) 2015-07-22 2016-07-21 ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS

Publications (2)

Publication Number Publication Date
CA2992509A1 CA2992509A1 (en) 2017-01-26
CA2992509C true CA2992509C (en) 2025-02-04

Family

ID=53776520

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2992509A Active CA2992509C (en) 2015-07-22 2016-07-21 Anti-TFR antibodies and their use in the treatment of proliferative and inflammatory diseases

Country Status (22)

Country Link
US (2) US11230605B2 (enExample)
EP (1) EP3325509B1 (enExample)
JP (1) JP6858185B2 (enExample)
KR (1) KR102690998B1 (enExample)
CN (1) CN107849136B (enExample)
AU (1) AU2016296321B2 (enExample)
CA (1) CA2992509C (enExample)
CY (1) CY1123941T1 (enExample)
DK (1) DK3325509T3 (enExample)
ES (1) ES2860988T3 (enExample)
HR (1) HRP20210393T1 (enExample)
HU (1) HUE053296T2 (enExample)
IL (1) IL257065B (enExample)
LT (1) LT3325509T (enExample)
MX (1) MX2018000569A (enExample)
PL (1) PL3325509T3 (enExample)
PT (1) PT3325509T (enExample)
RS (1) RS61586B1 (enExample)
RU (1) RU2737637C2 (enExample)
SI (1) SI3325509T1 (enExample)
SM (1) SMT202100134T1 (enExample)
WO (1) WO2017013230A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726879B (zh) 2015-05-04 2021-05-11 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
FR3062213B1 (fr) 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
AU2019316103B2 (en) 2018-08-02 2026-02-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4069745A4 (en) * 2019-11-06 2024-05-29 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR 1 TARGETING
US20230113823A1 (en) * 2020-01-31 2023-04-13 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) * 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
US11969475B2 (en) * 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
WO2023034409A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
WO2023039611A2 (en) * 2021-09-13 2023-03-16 The Board Of Regents Of The University Of Texas System Tfr antigen binding proteins and uses thereof
IL316143A (en) * 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
CN120282983A (zh) * 2022-12-02 2025-07-08 百奥赛图(北京)医药科技股份有限公司 抗tfr1抗体及其应用
TW202444759A (zh) 2023-03-24 2024-11-16 美商戴納立製藥公司 Ａβ靶向蛋白及使用方法
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
TW202517685A (zh) * 2023-10-26 2025-05-01 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途
WO2025140522A1 (en) * 2023-12-29 2025-07-03 Nona Biosciences (Suzhou) Co., Ltd. Anti-tfr1 antibodies, preparation methods and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
KR101077001B1 (ko) * 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
WO2005011082A2 (en) 2003-07-23 2005-02-03 Univeral Infusion Technology Drive motor transmission system
ATE537189T1 (de) * 2004-04-30 2011-12-15 Inst Nat Sante Rech Med Anti-tfr-antikörper
EP1765868B1 (en) * 2004-06-07 2016-04-20 MacroGenics, Inc. Transferrin receptor antibodies
ES2720160T3 (es) * 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
FR2953841B1 (fr) * 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
WO2014020140A1 (en) 2012-08-02 2014-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of transferrin receptor antagonist for the treatment of thalassemia
US9593165B2 (en) * 2012-11-08 2017-03-14 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer

Also Published As

Publication number Publication date
CN107849136A (zh) 2018-03-27
HK1256088A1 (en) 2019-09-13
RU2018106364A (ru) 2019-08-22
EP3325509A1 (en) 2018-05-30
PT3325509T (pt) 2021-03-12
RS61586B1 (sr) 2021-04-29
AU2016296321A1 (en) 2018-01-25
RU2737637C2 (ru) 2020-12-01
JP2018521691A (ja) 2018-08-09
US20190092870A1 (en) 2019-03-28
KR102690998B1 (ko) 2024-07-31
CA2992509A1 (en) 2017-01-26
IL257065B (en) 2022-07-01
US12037408B2 (en) 2024-07-16
KR20180028519A (ko) 2018-03-16
AU2016296321B2 (en) 2022-09-08
CN107849136B (zh) 2022-04-01
CY1123941T1 (el) 2022-05-27
HUE053296T2 (hu) 2021-06-28
LT3325509T (lt) 2021-06-10
HRP20210393T1 (hr) 2021-04-30
RU2018106364A3 (enExample) 2019-08-22
US11230605B2 (en) 2022-01-25
SMT202100134T1 (it) 2021-05-07
MX2018000569A (es) 2018-09-27
DK3325509T3 (da) 2021-03-08
ES2860988T3 (es) 2021-10-05
IL257065A (en) 2018-03-29
US20220119543A1 (en) 2022-04-21
SI3325509T1 (sl) 2021-07-30
EP3325509B1 (en) 2020-12-16
PL3325509T3 (pl) 2021-07-19
WO2017013230A1 (en) 2017-01-26
BR112018000650A2 (en) 2018-09-18
JP6858185B2 (ja) 2021-04-14

Similar Documents

Publication Publication Date Title
US12037408B2 (en) Method of treating a tumor using anti-TfR antibodies
AU2020286284B2 (en) Novel anti-CD39 antibodies
CN108350073B (zh) 针对bcma的单克隆抗体
KR102094022B1 (ko) 항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
CN104271602B (zh) 双特异性抗体
KR102847971B1 (ko) 항체-약물 컨쥬게이트 및 이의 암 치료 용도
CA2934965A1 (en) Novel anti-baff antibodies
MX2014003156A (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos.
JP7419238B2 (ja) Ｐｄ１結合剤
CN105121470A (zh) 抗cd25抗体及其用途
US20170158755A1 (en) Anti-laminin4 antibodies specific for lg1-3
CN117794948A (zh) 结合人纤维蛋白或纤维蛋白原γC结构域的抗体及其使用方法
KR20160010391A (ko) Cd20 및 cd95에 결합하는 재조합 이중특이성 항체
US20250188163A1 (en) Gprc5d antibodies with enhanced effector function and uses thereof
US20230272067A1 (en) Human monoclonal antibodies against tigit for immune related diseases
HK1256088B (en) Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
BR112018000650B1 (pt) Anticorpos anti-trf e sua utilização no tratamento de transtornos proliferativos e inflamatórios
WO2024251154A1 (zh) 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途
CN117295762A (zh) 抗cd122抗体及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250107

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250203

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250625